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Abstract 
Multiple sclerosis (MS) is a chronic neurological disease characterized by central nervous system 
(CNS) inflammation and demyelination. The C677T substitution variant in the 
methylenetetrahydrofolate reductase (MTHFR) gene has been associated with increased levels of 
circulating homocysteine and is a mild risk factor for vascular disease. Higher blood levels of 
homocysteine have also been reported in MS. Thus, the C677T mutation of the MTHFR gene may 
influence MS susceptibility. 
Noradrenaline, a neurotransmitter believed to play an immunosupressive role in neuroinflammatory 
disorders, is catabolized by catechol-O-methyl transferase (COMT). The COMT G158A substitution 
results in a three- to four-fold decreased activity of the COMT enzyme, which may influence CNS 
synaptic catecholamine breakdown and could also play a role in MS inflammation. 
We tested DNA from Australian MS patients and unaffected control subjects, matched for gender, 
age and ethnicity. Specifically, we genotyped the MTHFR C677T and the COMT G158A mutations. 
Genotype distributions showed that the homozygous mutant MTHFR genotype (T/T) and the COMT 
(H/H) genotype were slightly over-represented in the MS group (16% versus 11% and 24% versus 
19%, respectively), but both variations failed to reach statistical significance (P = 0.15 and P = 0.32, 
respectively). Hence, results from the present study do not support a major role for either functional 
gene mutation in MS susceptibility.  
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1. Introduction 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) 
typically affecting young Caucasian individuals. MS pathology is characterized both by patches of 
white matter degeneration and infiltration of inflammatory cells across the blood–brain barrier [10]. 
Several genetic studies have shown potential linkage of several chromosomal loci with MS 
susceptibility, in particular implicating the major histocompatibility complex (MHC) locus at 6p21 
[20]. Genome screen studies using markers specific to chromosome 22q12-13 have also demonstrated 
an association of this region with MS in several different populations [12], [8] and [1]. 
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A post-synaptic neuronal enzyme, catechol-O-methyl transferase (COMT), is genetically localised to 
chromosome 22q11.2. COMT is a key enzyme in the catabolic pathway of noradrenaline, a widely 
used neurotransmitter of the CNS. Previously, a COMT gene haplotype has been shown to be highly 
associated with schizophrenia [24]. Exon 4 of the COMT gene contains a G to A base pair substitution 
resulting in a valine–methionine amino acid change at codon 158 of the expressed membrane bound 
protein. This substitution is responsible for a three- to four-fold-decreased activity of the COMT 
enzyme [15] leading to a reduction of noradrenaline catabolism within synapses. Interestingly, the 
noradrenaline is postulated to decrease the inflammation occurring in neuroinflammatory diseases. 
Studies on mouse and rodent astrocytes show that noradrenaline induces reduced expression of MHC 
class II molecules [5] and [6]. By attenuating the role of antigen-presenting cells (APCs) such as 
astrocytes, noradrenaline may confer a natural immunosuppressive protection within normal healthy 
brain environments, as brains from healthy individuals demonstrate a lower threshold of inflammation 
compared to other organs [16]. A decreased amount of noradrenaline, which could result from an 
increase of activity of the COMT enzyme, could thus lead to CNS inflammation in MS patients. 
Interestingly, a case–control study involving 108 MS patients found that two bi-allelic polymorphisms 
within the promoter of phenylethanolamine N-methyltransferase (PNMT), a final enzyme involved in 
the biosynthesis of noradrenaline, were associated with MS [18]. Finally, a previous study of 
amyotropic lateral sclerosis has shown that COMT enzyme activity was mildly, although not 
significantly, increased in patient spinal cord tissue post-mortem [3]. 
 
 
Fig. 1. Remethylation of Homocysteine. 
The human methylenetetrahydrofolate reductase (MTHFR) gene, composed of 11 exons [7], has been 
mapped to the 1p36.3 chromosomal locus, a region found to be positively associated to an Icelandic 
MS population in a genome wide scan [12]. The MTHFR enzyme plays a role in folate metabolism 
where it catalyses the reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate [9] (Fig. 
1). Folate is a cofactor in the remethylation of homocysteine, without which, homocysteine levels in 
the plasma increase. Patients with a deficiency in MTHFR present an elevation of blood and urinary 
levels of homocysteine. Interestingly, high levels of homocysteine have been encountered in some, but 
not all, MS patients [9] and [23] and hypercystinuric patients show neuronal loss associated with 
diffuse demyelination [22]. An elevated concentration of homocysteine in the blood may trigger 
oxidation of low-density lipoproteins (LDL) extending to lipid peroxidation and atherosclerosis stages 
[11]. Furthermore, elevated concentration of homocysteine in the blood may be also responsible for the 
sensitisation of neurons to oxidative stress [14]. Oxidative stress is a hallmark of MS [26] and anti-
oxidant therapy leads to a decrease of severity of MS-like disease in animal models of experimental 
allergic encephalomyelitis (EAE) [19]. The MTHFR C677T genotype has also been shown to enhance 
atherosclerosis in Parkinson disease (PND), and other neurodegenerative disease [21]. The MTHFR 
C677T is a common mutation of the MTHFR gene with a C to T transition, located at nucleotide 677. 
This mutation results in the alanine to valine amino acid change leading to reduced activity of the 
enzyme (mean activity is 65% in the Ala/Val heterozygote and 30% in the Val/Val homozygous state, 
respectively, compared to the mean activity in the Ala/Ala homozygote). As a result, this MTHFR gene 
functional mutation may play a possible role in MS susceptibility.  
The regulators of homocysteine formation as well as the regulators for noradrenaline formation could 
have a detrimental effect on the blood–brain barrier and neuroinflammation in MS patients. One could 
predict that mutations in COMT could result in the alteration of noradrenaline levels thus developing a 
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potential increase of inflammation in the CNS of MS patients. In addition, this detrimental effect of 
increased neuroinflammation could be accentuated by a decreased functionality of the MTHFR gene 
resulting in myelin sheath instability as seen in MTHFR knock-out animals. Neuroinflammation and 
myelin instability are the two major hallmarks encountered in MS pathology. The aim of this study was 
thus to investigate whether functional variants of the MTHFR and COMT genes show association with 
MS in an Australian sample. 
2. Materials and methods 
2.1. Subject groups 
All participants of the study were unrelated and of UK-Caucasian origin. The study protocol was 
approved by Griffith University's Ethics Committee for experimentation on humans. The association 
population consisted of 104 MS-affected individuals and 104 controls, matched for ethnicity 
(Caucasian), sex and age (±5 years). The MS population was obtained from patients of the Multiple 
Sclerosis Clinic at the Royal Brisbane and Women's Hospital, all from the South East Queensland 
region. The MS group consisted of 75% females and 25% males and was comprised of three clinical 
subtypes: relapsing-remitting MS (RR-MS), secondary progressive MS (SP-MS) and primary 
progressive MS (PP-MS) with frequencies of 40, 36 and 24%, respectively. The control group was also 
obtained from the South East Queensland region through the Genomics Research Centre, Southport, 
with each control age (±5 years), sex, and ethnicity matched to the affected population as previously 
described [25]. All individuals gave informed consent before participating in the research. The studied 
MS population were descended from northern European emigrants. The MS patients are recent 
immigrants (their parents, grand-parents or great grand-parents came to Australia within the last 200 
years from a predominantly northern European background including the United Kingdom and 
European countries). There are no native Australians (i.e. people of Aboriginal or Torres Straight 
Island descent). Genomic DNA was extracted from peripheral blood using a standard salting-out 
protocol. 
2.2. Genotyping of the MTHFR gene variant 
Genomic DNA (40 ng) was amplified by the polymerase chain reaction, in a DNA Thermal Cycler 
(Perkin-Elmer, Norwalk, CT, USA) using the MTHFR primers designed by Frosst et al. [7] (5′-TGA 
AGG AGA AGG TGT CTG CGG GA-3′ for the sense oligonucleotide primer and 5′-AGG ACG GTG 
CGG TGA GAG TG-3′ for the antisense primer, both synthesised by Geneworks) in the following 
singleplex reaction: 1.75 mM of MgCl2, 1× standard PCR buffer, 0.2 mM of dNTPs, 0.2 µM each of 
forward and reverse primers, 0.16 g/L of BSA, 1 unit of Taq polymerase (Perkin-Elmer), 40 ng of 
genomics DNA, made to a final volume of 25 µL with sterile distilled water. The cycle parameters 
were as follows: 1 cycle at 95 °C for 3 min for an initial denaturation, followed by 35 cycles of 
denaturation for 1 min at 94 °C, primer annealing for 1 min at 65 °C, primer extension for 2 min at 
72 °C and a final extension for 10 min at 72 °C. This amplification reaction resulted in the synthesis of 
a 198-bp fragment. The MTHFR gene contains a C to T substitution at nucleotide 677; the alteration 
created a HinfI site that was used to screen the 104 patients. For the restriction digestion, 7 units of 
HinfI, 2 µl of NE buffer II and 2.3 µl of sterile water were added to each extension mix at a final 
volume of 20 µl and samples digested overnight at 37 °C. HinfI did not digest the fragment derived 
from the C allele, whereas HinfI digested the fragment of the same length from the T allele into 175- 
and 23-bp fragments. These fragments were then electrophoresed using a 5% ultra-high-resolution 
agarose gel, stained with ethidium bromide and visualized under UV light. 
2.3. Genotyping of the COMT gene variant 
Genomic DNA (40 ng) was amplified by the polymerase chain reaction, in a DNA Thermal Cycler 
(Perkin-Elmer, Norwalk, CT, USA) using the COMT primers 5′-TAC TGT GGC TAC TCA GCT GT-
3′ for the sense oligonucleotide primer and 5′-TGA ACG TGG TGT GAA CAC CT-3′ for the antisense 
primer (primers synthesized by GeneWorks). In the following singleplex reaction: 2 mM of MgCl2, 1× 
standard PCR buffer, 0.2 mM of dNTPs, 0.3 µM each of forward and reverse primers, 1 unit of Taq 
polymerase (Perkin-Elmer), 40 ng of genomic DNA, made to a final volume of 20 µL with sterile 
distilled water. The cycle parameters were as follows: 1 cycle at 95 °C for 5 min for an initial 
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denaturation, followed by 35 cycles of denaturation for 30 s at 94 °C, primer annealing for 1 min at 
57 °C, primer extension for 1 min at 72 °C and a final extension for 7 min at 72 °C. This amplification 
reaction resulted in the synthesis of a 237-bp fragment. In exon 4 of the COMT gene, a G to A base 
pair substitution results in a valine–methionine amino acid change at codon 158 of the expressed 
protein. This Val/Met polymorphism is detectable with a restriction enzyme, NlaIII enzyme (R0125S, 
New England BioLabs), which was used to screen the 104 patients. For the restriction digestion, 2 units 
of NlaIII, 1.5 µl of 10× NEB buffer 4, 0.2 µl of 100× BSA and 3.1 µl of sterile water were added to 
each extension mix at a final volume of 15 µl and samples digested overnight at 37 °C. COMT 
mutation transforms nucleotide G to A, leading to a low (L) activity of the enzyme (containing mutated 
amino acid methionine). High (H) activity of COMT enzyme (containing valine) in the HH genotype 
could be a risk factor for MS. The COMT-HH genotype was represented by a single fragment at 
114 bp, COMT-LL genotype by a single fragment at 96 bp and COMT-HL by two fragments at 114 
and 96 bp. These fragments were then electrophoresed by using a 4% ultra-high-resolution agarose gel, 
stained with ethidium bromide and visualized under UV light. 
2.4. Statistical analysis 
Most genomic DNA samples were successfully genotyped and used for analysis however some 
samples were unsuccessfully amplified and thus not all DNAs were genotyped from all samples (Table 
1 and Table 2). The MTHFR C677T and COMT variant genotype and allele frequencies were 
calculated from observed genotype counts. Genotype and allele frequencies for the MTHFR and 
COMT gene variants were initially assessed for association with MS using standard contingency table 
analysis incorporating the chi-squared test of independence. This analysis produces a χ2 statistic with 1 
or 2 degrees of freedom and corresponding P-values for allele and genotype distributions, respectively. 
Conditional multivariate logistic regression analysis for matched case–control groups was performed to 
estimate the adjusted independent and interactive effects of the MTHFR and COMT genotypes on MS 
susceptibility. A more stringent α-level of 0.025 was specified as the significance threshold based on 
the testing of two independent hypotheses, i.e. 0.05/2. Power estimates indicated that if either of the 
variants tested were to directly confer a two-fold increase in relative risk of MS, the case and control 
groups used in this study were of sufficient size to have >80% power to detect a significant association 
at the 0.025 level. All the statistical analyses were performed using SPSS (v10) software.  
Table 1. Distribution of MTHFR C677T (genotype and allele) frequencies in MS case and 
control groups 
 
Group                   Genotypes*         N (genotypes)                 Alleles 
 C/C C/T T/T  C T 
MS (total) 54(54%) 31 (31%) 16 (16%) 101 139(69%) 63 (31%) 
Control 46(46%) 44 (44%) 11 (11%) 101 136(67%) 66 (33%) 
 
* Genotype distribution comparison (χ2 = 3.82, 2 df, P = 0.15). 
 
 
Table 2. Distribution of COMT H/L (genotype and allele) frequencies in MS case and control 
groups  
 
Group                   Genotypes*           N (genotypes)                 Alleles 
 H/H H/L L/L  H L 
MS (total) 25 (24%) 53 (51%) 26 (25%) 104 102 (49%) 106 (51%) 
Control 19(19%) 62 (61%) 20 (20%) 101 100 (50%) 102 (50%) 
* Genotype distribution comparison (χ2 = 2.26, 2 df, P = 0.32). 
3. Results 
Contingency table analysis of the MTHFR C677T frequency data (Table 1) indicated that the T allele 
was not over-represented in the MS group compared to the control group (31% versus 33%). 
Comparison of the genotype distributions showed that the homozygous mutant genotype (T/T) was 
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slightly over-represented in the MS group (16% versus 11%), but this trend did not reach statistical 
significance (P = 0.15). 
For the COMT H/L polymorphism, the allele frequency distributions were not significantly different 
between any case group and controls (P > 0.05) (Table 2). Comparison of the genotype distributions 
for this variant also showed that the homozygous high-activity genotype (H/H) was slightly over-
represented in the MS group (24% versus 19%), but this trend was also not statistically significant 
(P = 0.32). 
To test for a possible MTHFR*COMT genotypic interaction, conditional multiple logistic regression 
analysis was performed incorporating data for both the MTHFR C677T and COMT H/L variants. The 
risk factor genotype groups were set as “T/T” and “H/H” for the MTHFR and COMT variants, 
respectively. The results of these multivariate analyses did not reveal any statistically significant 
independent or interaction effects (results not shown). Also, no association with sex or with age of 
onset was detected for either of the two tested gene markers (P > 0.05). 
4. Discussion 
The aim of this study was to investigate the potential role of functional variants of MTHFR and COMT 
genes in MS susceptibility within an Australian sample. In the present study, the MTHFR C677T 
mutation was studied in an MS sample from Australia and although the results showed a slight increase 
in the number of individuals with the low activity mutant genotype, these results failed to reach 
statistical significance (P = 0.15). Our results do not support any association of the tested C677T gene 
mutation with MS. A recent Japanese genotyping study investigating the same MTHFR C677T in 1721 
subjects free of any history of stroke, but diagnosed with white matter lesions following brain MRI 
examination, showed an association of the MTHFR TT genotype with silent brain infarcts and 
advanced white matter lesions [13]. This prompted an investigation of the same gene in our Australian 
MS sample. However despite a slight overrepresentation of this MTHFR genotype, the tested gene 
marker did not show significant association. Despite these negative results, one cannot completely 
exclude any association of the MTHFR with MS. Association tests only test a single point of a gene for 
involvement in a disease and also the tested population was relatively small reducing the power to 
detect a significant association if it did exist. Thus although results for the MTHFR gene marker were 
negative, this does not completely rule out this gene in disease causality. 
The second candidate gene investigated was COMT, a gene involved in the catabolism of 
noradrenaline. Alterations in the CNS levels of noradrenaline, which exerts an immunosuppressive 
effect, may play a role in MS. Supporting this possibility, recent findings have shown that 
phenylethanolamine N-methyltransferase (PNMT), a gene involved in noradrenaline biosynthesis, was 
found to be associated with MS in a non-Hispanic Caucasian American population [18]. In the present 
study we investigated a functional variant of COMT in an MS Australian population. Although the 
COMT homozygous high-activity genotype (H/H) was slightly over-represented in the MS group, these 
results also failed to reach statistical significance (P = 0.32) in this present study. Again however the 
tested population was relatively small and only one point in the gene was tested for causality and thus 
the gene cannot be completely excluded. In addition, several research teams are postulating that the 
adrenergic pathway is a prominent feature of multiple sclerosis pathology [2] and [4] with some 
treatments showing improvement in MS symptomatology [17]. 
Hence, although both the MTHFR and COMT genes could be considered potential candidates for 
involvement in MS susceptibility and pathology, the results of our study do not support a significant 
role for either of the tested functional variants in susceptibility to the disorder.  
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